United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
United Therapeutics (Nasdaq: UTHR) has announced that it will release its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued at approximately 6:30 a.m. Eastern Time. The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, accessible via their website. A rebroadcast of the webcast will be available for one year.
United Therapeutics is a publicly-traded biotech company that has taken the form of a public benefit (PBC). Their mission focuses on innovating for unmet medical needs and developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
United Therapeutics (Nasdaq: UTHR) ha annunciato che rilascerà i propri risultati finanziari del secondo trimestre 2024 prima dell'apertura del mercato, il mercoledì 31 luglio 2024. Un comunicato stampa che dettaglia i risultati trimestrali sarà pubblicato intorno alle 6:30 a.m. Eastern Time. L'azienda ospiterà un webcast pubblico alle 9:00 a.m. Eastern Time lo stesso giorno, accessibile tramite il loro sito web. Un rebroadcast del webcast sarà disponibile per un anno.
United Therapeutics è una società biotecnologica quotata in borsa che ha assunto la forma di una public benefit corporation (PBC). La loro missione si concentra sull'innovazione per soddisfare bisogni medici non soddisfatti e sullo sviluppo di nuove terapie e tecnologie farmaceutiche per ampliare la disponibilità di organi trapiantabili.
United Therapeutics (Nasdaq: UTHR) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 antes de la apertura del mercado el miércoles 31 de julio de 2024. Se emitirá un comunicado de prensa detallando los resultados trimestrales aproximadamente a las 6:30 a.m. hora del Este. La compañía llevará a cabo un webcast público a las 9:00 a.m. hora del Este el mismo día, accesible a través de su sitio web. Se dispondrá de una retransmisión del webcast durante un año.
United Therapeutics es una empresa biotecnológica que cotiza en bolsa y que ha adoptado la forma de una corporación de beneficio público (PBC). Su misión se centra en innovar para satisfacer necesidades médicas no cubiertas y en desarrollar nuevas terapias y tecnologías farmacéuticas para ampliar la disponibilidad de órganos transplantables.
United Therapeutics (Nasdaq: UTHR)는 2024년 2분기 재무 결과를 2024년 7월 31일 수요일 시장 개장 전에 발표할 것이라고 발표했습니다. 분기 결과를 자세히 설명하는 보도 자료는 동부 표준시로 오전 6시 30분경에 발표될 예정입니다. 회사는 같은 날 동부 표준시로 오전 9시에 공식 웹캐스트를 주최하며, 이를 통해 그들의 웹사이트에서 접속할 수 있습니다. 웹캐스트의 재전송은 1년 동안 제공됩니다.
United Therapeutics는 상장된 생명공학 회사로, 공익 법인(PBC)의 형태를 취하고 있습니다. 이들의 사명은 충족되지 않은 의학적 필요를 위해 혁신하고, 이식 가능한 장기를 확대할 수 있도록 새로운 의약품 치료법과 기술을 개발하는 것입니다.
United Therapeutics (Nasdaq: UTHR) a annoncé qu'il publiera ses résultats financiers pour le deuxième trimestre 2024 avant l'ouverture du marché le mercredi 31 juillet 2024. Un communiqué de presse détaillant les résultats trimestriels sera émis vers 6h30, heure de l'Est. La société animera un webinaire public le même jour à 9h00, heure de l'Est, accessible via leur site web. Une rediffusion du webinaire sera disponible pendant un an.
United Therapeutics est une entreprise de biotechnologie cotée en bourse qui a pris la forme d'une corporation à but d'intérêt public (PBC). Leur mission se concentre sur l'innovation pour satisfaire des besoins médicaux non comblés et sur le développement de nouvelles thérapies et technologies pharmaceutiques afin d'élargir la disponibilité des organes transplantables.
United Therapeutics (Nasdaq: UTHR) hat bekannt gegeben, dass die Finanzergebnisse für das zweite Quartal 2024 vor Markteröffnung am Mittwoch, den 31. Juli 2024 veröffentlicht werden. Eine Pressemitteilung mit den Quartalsergebnissen wird voraussichtlich um 6:30 Uhr Eastern Time herausgegeben. Das Unternehmen wird am selben Tag um 9:00 Uhr Eastern Time ein öffentliches Webcast veranstalten, das über ihre Website zugänglich ist. Eine Wiederholung des Webcasts wird für ein Jahr verfügbar sein.
United Therapeutics ist ein börsennotiertes Biotechnologieunternehmen, das die Form einer Public Benefit Corporation (PBC) angenommen hat. Ihre Mission konzentriert sich auf Innovationen zur Deckung unerfüllter medizinischer Bedürfnisse und die Entwicklung neuer pharmazeutischer Therapien und Technologien zur Erweiterung der Verfügbarkeit transplantierbarer Organe.
- Timely reporting of quarterly financial results
- Hosting a public webcast for transparency and investor communication
- Unique status as a public benefit in the biotech sector
- None.
United Therapeutics will host a public webcast Wednesday, July 31, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 24, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724139264/en/
Dewey Steadman at (202) 919-4097
https://ir.unither.com/contact-ir
Source: United Therapeutics Corporation
FAQ
When will United Therapeutics (UTHR) report its Q2 2024 financial results?
What time is the United Therapeutics (UTHR) Q2 2024 earnings webcast?
Where can I access United Therapeutics' (UTHR) Q2 2024 earnings webcast?
What makes United Therapeutics (UTHR) unique as a biotech company?
